or Try an Advanced Search...

    Technical Analysis for GTHX - G1 Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 2.47 8.33% 0.19
    GTHX closed up 8.33 percent on Monday, July 1, 2024, on 71 percent of normal volume.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Up
    Historical GTHX trend table...
    Date Alert Name Type % Chg
    MACD Bullish Signal Line Cross Bullish 0.00%
    Calm After Storm Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Gapped Up Strength 0.00%
    Pocket Pivot Bullish Swing Setup 8.33%
    Volume Surge Other 8.33%
    Calm After Storm Range Contraction 8.33%
    Wide Bands Range Expansion 8.33%
    180 Bearish Setup Bearish Swing Setup 9.78%
    Calm After Storm Range Contraction 9.78%
    Older End-of-Day Signals for GTHX ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakout about 5 hours ago
    Possible NR7 about 6 hours ago
    10 DMA Support about 9 hours ago
    Rose Above 10 DMA about 9 hours ago
    Down 1% about 11 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    GTHX Chart by TradingView
    Basic chart:

    Profile

    G1 Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38 are designed to be combined and enhance the anti-tumor activity of current therapies. It is also developing G1T48, an oral selective estrogen receptor degrader (SERD) for the treatment of breast cancer. The Company is evaluating trilaciclib in three Phase II clinical trials. G1T38 is being evaluated in combination with Faslodex in a Phase I b/II a trial for patients with estrogen receptor-positive, HER2-negative breast cancer.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Drugs Treatment Of Cancer Breast Cancer Treatment Of Breast Cancer Protein Kinase Inhibitor Hormones Her2 Her2/Neu Estrogen Antiestrogens Estrogen Receptor Receptor Positive Selective Estrogen Receptor Degraders Fulvestrant

    Is GTHX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jul 1 G1 Therapeutics added to the Russell 2000® and 3000® Indexes
    Jul 1 G1 Therapeutics Added to the Russell 2000® and 3000® Indexes
    Jun 25 G1 Therapeutics drops as breast cancer therapy fails in late-stage trial
    Jun 25 G1 Therapeutics discontinue COSELA in TNBC following Phase III flop
    Jun 24 G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty
    Jun 24 G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)
    Jun 7 It's Probably Less Likely That G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Will See A Huge Pay Rise This Year
    Jun 5 G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    May 31 G1 Therapeutics (NASDAQ:GTHX shareholders incur further losses as stock declines 19% this week, taking three-year losses to 84%
    May 28 G1 Therapeutics slips after new breast cancer data for lead asset
    See more GTHX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 6.14
    52 Week Low 1.08
    Average Volume 1,726,152
    200-Day Moving Average 2.95
    50-Day Moving Average 3.59
    20-Day Moving Average 2.70
    10-Day Moving Average 2.39
    Average True Range 0.30
    RSI (14) 32.89
    ADX 39.04
    +DI 14.79
    -DI 34.91
    Chandelier Exit (Long, 3 ATRs) 2.58
    Chandelier Exit (Short, 3 ATRs) 2.34
    Upper Bollinger Bands 3.39
    Lower Bollinger Band 2.01
    Percent B (%b) 0.33
    BandWidth 51.00
    MACD Line -0.39
    MACD Signal Line -0.40
    MACD Histogram 0.012
    Fundamentals Value
    Market Cap 128.05 Million
    Num Shares 51.8 Million
    EPS -1.43
    Price-to-Earnings (P/E) Ratio -1.73
    Price-to-Sales 3.08
    Price-to-Book 5.46
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.85
    Resistance 3 (R3) 2.81 2.65 2.78
    Resistance 2 (R2) 2.65 2.55 2.67 2.76
    Resistance 1 (R1) 2.56 2.50 2.61 2.60 2.74
    Pivot Point 2.40 2.40 2.42 2.42 2.40
    Support 1 (S1) 2.31 2.30 2.36 2.35 2.20
    Support 2 (S2) 2.15 2.25 2.17 2.18
    Support 3 (S3) 2.06 2.15 2.16
    Support 4 (S4) 2.10